HEPATOCELLULAR CANCER

This early-phase trial is testing whether amivantamab, a drug that targets specific proteins on cancer cells, can be given as a shot under the skin instead of through an IV. The study involves 158 adults with advanced solid tumors (like lung or head and neck cancers) that have no…

This study tests a mix of three drugs (durvalumab, bevacizumab, tremelimumab) plus a procedure called TACE (which delivers chemotherapy beads to the liver) in people with advanced liver or bile duct cancer. The goal is to see if this combination can stop the cancer from growing f…

This study tests a new drug called Q702 combined with pembrolizumab (an immunotherapy) in people with advanced esophageal, stomach, liver, or cervical cancer that has worsened after prior treatment. The goal is to see if the combination is safe and can shrink tumors. About 120 pa…

This study aimed to see if a person's own immune cells, modified in a lab to target specific cancer gene mutations, could prevent advanced gastrointestinal cancers from coming back after standard treatment. It was designed for people whose blood tests showed signs of remaining ca…

This study is testing a new blood test called Oncoguard Liver to see how well it detects liver cancer (hepatocellular carcinoma) in people at increased risk, such as those with cirrhosis or hepatitis B. About 3,000 participants will provide a blood sample and undergo imaging like…

This study follows 10,000 adults with hepatocellular carcinoma (a type of liver cancer) to see how the disease changes over time and how different treatments affect patients in real life. Researchers are collecting information from regular doctor visits and patient surveys, and b…